GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens
GenFleet Therapeutics-B (02595) announced that the oral pan-RAS inhibitor GFH276 has entered an Ib/II phase multicenter, open-label combination therapy study, which will be conducted at dozens of research centers in China and Australia. The first overseas enrolled patient recently completed dosing at Monash Health in Australia, and the first enrolled patient in China completed dosing in the third quarter of this year at Fudan University Shanghai Cancer Center.
GENFLEET-B(02595) announced that oral pan-RAS inhibitor GFH276 has entered an Ib/II phase, multicenter, open-label combination therapy study, which will be conducted at dozens of clinical sites in China and Australia. The first overseas enrolled patient recently completed dosing at Monash Health in Australia, and the first Chinese enrolled patient completed dosing in the third quarter of this year at Fudan University Shanghai Cancer Center. The study aims to evaluate the efficacy and safety of multiple combination therapies in treating RAS-mutant pancreatic cancer and advanced solid tumors; the Phase II stage will include three first-line pancreatic cancer treatment cohorts, namely GFH276 combined with cetuximab (anti-EGFR monoclonal antibody), GFH276 combined with AG (standard chemotherapy regimen), and GFH276 combined with mFOLFIRINOX (standard chemotherapy regimen).
The first patient was dosed in September 2025 in the clinical trial of GFH276 monotherapy for previously treated solid tumors, placing its clinical development progress in the first tier of domestic pan-RAS inhibitors. According to the Late-Breaking Abstract (LBA) at this year's ESMO Annual Meeting, in the GFH276 monotherapy Phase Ia trial, as of the data cutoff date, 72.6% of patients with pancreatic ductal adenocarcinoma (PDAC) received GFH276 as third-line or later treatment, and no dose-limiting toxicities were observed at the 40-160 mg QD dose level (patients did not use prophylactic medication); among 61 evaluable PDAC patients (40-160 mg QD), the overall objective response rate (ORR) was 41.1%, and the ORR was 43.1% in patients who had not previously received RAS-targeted therapy. According to multi-tumor animal study data presented in a poster at this year's AACR Annual Meeting, GFH276 combined with anti-EGFR monoclonal antibodies, chemotherapy, and other standard treatments showed significant synergistic effects and superior tumor inhibition, providing translational medicine rationale for this clinical study.
Dr. Wang Yu, Chief Medical Officer of GenFleet, said: "Pan-RAS inhibitors have demonstrated in clinical studies of monotherapy and combination with chemotherapy for pancreatic cancer and other solid tumors the potential of innovative targeted therapy to rewrite the survival of major indications. GenFleet has successfully advanced multiple first-line combination therapy trials of KRAS G12C/G12D inhibitors that are among the global leaders in progress. Based on our deep development experience in the RAS field, we will provide the most suitable treatment options for patients with different RAS mutations and bring more excellent innovative therapies to the frontline."
According to Frost & Sullivan data, about 30% of cancer patients worldwide harbor RAS mutations, and from 2025 to 2032, the number of newly diagnosed RAS-mutant patients is expected to exceed 6 million per year, with nearly 90% of pancreatic cancer patients harboring RAS mutations. Currently, multiple RAS therapies have been launched in China and overseas, and investigational projects in various molecular forms have entered mid-to-late-stage clinical development, so the growth potential of the RAS field is becoming increasingly prominent and the market space is huge. Delveinsight data show that the 10-year compound annual growth rate (CAGR) for KRAS (the largest subtype of RAS mutations) inhibitors is 35%, and overseas investment research institutions' peak sales forecasts for pan-RAS inhibitors have climbed from US$230 million at the end of 2024 (GlobalData) to US$8.3 billion in 2026 (Bloomberg).
Related Articles

GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.
GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.






